Every pharma company I cover has U.S. production so tariffs are more bark than bite: BMO's Seigerman Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'Closing Bell' to discuss President Trump's latest tariff announcement on pharmaceutical companies, where execution needs to happ...